A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes
Phase 3
18+
12 sites in AL, AZ, CA +8
About this study
This Phase 3 study is focused on people with obesity. The primary outcome being measured is Percent (%) Change from Baseline in Body Weight at Week 72.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Percent (%) Change from Baseline in Body Weight at Week 72
Secondary: Change from Baseline in Body Mass Index (BMI) at Week 72, Change from Baseline in Body Weight (kg) at Week 72, Change from Baseline in Diastolic Blood Pressure at Week 72, Change from Baseline in Fasting Glucose at Week 72, Change from Baseline in Fasting Insulin at Week 72, Change from Baseline in Free Fatty Acids at Week 72, Change from Baseline in HRQoL as Assessed by the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) Questionnaire Domain Scores and Total Score at Week 72, Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by the SF-36v2 Acute Form Domain Scores and Component Summary Scores at Week 72
Endocrinology